Scalper1 News
An analysis of October sales from IMS Health (IMS) shows that Sanofi (SNY) is continuing to gain market share from Biogen (BIIB) in multiple sclerosis, according to RBC Capital Markets. Biogen sold $284 million worth of its drug Tecfidera in the U.S. in October, or $71 million per week. Analyst Michael Yee notes that this was up 3% from September’s weekly rate, while weekly prescription reports in November have been “flattish.” “We’d like to see Scalper1 News
Scalper1 News